α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28165480.
- Also identified by DOI 10.1038/nm.4280 and PMC identifier 5656064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cystinuria is an incompletely dominant disorder characterized by defective urinary cystine reabsorption that results in the formation of cystine-based urinary stones. Current treatment options are limited in their effectiveness at preventing stone recurrence and are often poorly tolerated. We report that the nutritional supplement α-lipoic acid inhibits cystine stone formation in the Slc3a1<sup>-/-</sup> mouse model of cystinuria by increasing the solubility of urinary cystine. These findings identify a novel therapeutic strategy for the clinical treatment of cystinuria.
Medical subject headings
- Cystine
- Cystinuria
- Kidney
- Thioctic Acid
- Urolithiasis